Trial reportBMC psychiatry2026
Seizure adequacy and safety of remimazolam in electroconvulsive therapy for patients with psychiatric disorders: a double-blind randomized crossover trial.
Trial report in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionElectroconvulsive therapy (ECT) is an established and effective treatment for patients with medication-resistant psychiatric disorders. However, the optimal choice of anesthetic agent for ECT induction remains a subject of ongoing debate. Remimazolam, a novel ultra-short-acting benzodiazepine, has yet to be systematically evaluated in the context of ECT anesthesia.
methodWe conducted a prospective, double-blind, randomized, crossover trial in hospitalized patients scheduled for ECT. Participants were randomly assigned to different treatment sequences, receiving either remimazolam (0.2 mg/kg) or propofol (2 mg/kg) for anesthesia induction in a crossover manner. The primary outcome was EEG seizure duration. Secondary outcomes included seizure adequacy endpoint, anesthesia-related parameters and safety profiles. All analyses were performed using generalized linear mixed-effects models, with treatment condition, stimulus dose, and treatment sequence as fixed effects and participant-specific random intercepts.
resultsA total of 284 ECT sessions from 56 patients were included in the analysis. The remimazolam group demonstrated significantly longer EEG seizure duration (37.0 s vs. 18.5 s; p < 0.001) and EMG seizure duration (15.0 s vs. 9.0 s, p < 0.001), higher average seizure energy index (24,767.4 µV
conclusionRemimazolam is an effective anesthetic induction agent for ECT, offering superior seizure quality metrics compared to propofol. However, clinicians should remain vigilant regarding the potential for post-ictal cardiovascular hyperdynamic states.
trial registrationChinese Clinical Trial Registry (number: ChiCTR2500114332; date: December 10, 2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.